乌司他丁联合金属胆道支架对肝外胆道梗阻胰腺癌的治疗效果

doi:10.3969/j.issn.1004-616x.2023.04.008

Abstract

Abstract: OBJECTIVE： To investigate effects of ulinastatin in combination with metal biliary stent on pancreatic cancers which were caused by extrahepatic biliary obstruction. METHODS： A total of 92 pancreatic cancer patients with extrahepatic biliary obstruction were selected and ewually divided into control and observation groups according to the random number table method. The control group was treated with metal biliary stent implantation alone，and the observation group was treated in combination with ulinastatin for two weeks. Before and after the treatments，concentrations of liver function total bilirubin (TBiL) and aspartate aminotransferase (AST)，and changes of blood uric acid (UA) and urea nitrogen (BUN) were determined. In addition，clinical efficacy and occurrence of adverse reactions after the treatment were compared between the two groups. RESULTS： After the treatment，AST and TBiL concentrations in the two groups were lower than before treatment (P<0.05)，and AST and TBiL concentrations in the observation group were lower than control group (P<0.05). After treatment，blood UA and BUN concentrations in the two groups were reduced (P<0.05)，and the observation group was lower than that in the control group (P<0.05). The total effective rates in the observation group (97.83%) was higher than that of the control group (82.61%) (P<0.05). During treatment，there was 1 case of nausea，1 case of vomiting and 1 case of diarrhea in the observation group，and the incidence of adverse reactions was 6.52% (3/46)，while 2 cases of nausea and 4.35% (2/46) were in the control group，there was no difference in the incidence of adverse reactions (correction value χ²=0.211，P=0.646). After treatment，the concentration of inflammatory factors in the two groups was lower than that before treatment (P<0.05)，and the concentration of inflammatory factors in the observation group was lower than that in the control group (P<0.05). CONCLUSION： Ulinastatin in combination with metal biliary stent implantation improved liver and kidney functions，enhanced efficacy and safety，reduced inflammatory factors，and improved immune functions among pancreatic cancer patients with extrahepatic biliary obstruction.

Key words: ulinastatin, metal biliary stent implantation, pancreatic cancer, biliary obstruction

CLC Number:

R735.9

LI Wei, WU Sheng, TIAN Yujian, TANG Xiaoming, CAI Chuang, HU Hao. Effect of ulinastatin combined with metal biliary stent on pancreatic cancer with extrahepatic biliary obstruction[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 292-295,319.

References

[1] 付晓伟, 欧阳永灏, 洪乐, 等. 基于高通量测序技术的胰腺癌环状RNA差异表达谱分析[J]. 安徽医科大学学报, 2023, 58(1): 101-108.
[2] 余志龙, 戎泽印, 窦进, 等. 乌司他丁在胰腺癌围手术期中的临床研究[J]. 中华全科医学, 2019, 17(9): 1470-1473.
[3] 张艺, 胡松华, 朱建新. 地塞米松灌洗支气管肺泡联合静脉推注乌司他丁对老年急性肺损伤患者TGF-β1/Smads信号通路的影响[J]. 贵州医科大学学报, 2022, 47(11): 1332-1338.
[4] 崔扬, 周佳昕, 田年静, 等. 早期胰腺癌患者Roy适应模式的构建与应用研究[J]. 重庆医学, 2023, 52(5): 696-700.
[5] SATOH T, KANG Y K, CHAO Y E, et al. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer[J]. Gastric Cancer, 2020, 23(1): 143-153.
[6] WANG H, TANG H, FANG Y, et al. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial[J]. JAMA Surg, 2021, 156(5): 444-451.
[7] 虞先濬, 刘亮, 徐华祥, 等. 胰腺癌综合诊治指南(2018版)[J]. 临床肝胆病杂志, 2018, 34(10): 2109-2120.
[8] 刘德忠, 李槐, 曾辉英, 等. 经动脉灌注健择治疗中晚期胰腺癌临床疗效初步观察[J]. 中国医学影像技术, 2000, 16(11): 928-930.
[9] WILKE H, MURO K, VAN CUTSEM E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235.
[10] XU R H, ZHANG Y Q, PAN H M, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(12): 1015-1024.
[11] ZHANG B, QI L, WANG X, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma[J]. Cancer Commun, 2020, 40(12): 711-720.
[12] CHEN Z, DING T, MA C G. Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice[J]. Biochem Biophys Res Commun, 2017, 493(2): 1143-1150.
[13] CHOWDHURY R, PEEL N M, KROSCH M, et al. Frailty and chronic kidney disease: a systematic review[J]. Arch Gerontol Geriatr, 2017, 68: 135-142.
[14] YANG H, LIU H, CHEN Y P, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial[J]. JAMA Surg, 2021, 156(8): 721-729.
[15] AURSULESEI V, COSTACHE I I. Anticoagulation in chronic kidney disease: from guidelines to clinical practice[J]. Clin Cardiol, 2019, 42(8): 774-782.
[16] XING W Q, ZHAO L D, ZHENG Y, et al. The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer-a phase II study[J]. Front Immunol, 2021, 12: 772450.
[17] HUANG J, XU J M, CHEN Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842.
[18] MALLAMACI F, PISANO A, TRIPEPI G. Physical activity in chronic kidney disease and the EXerCise introduction to enhance trial[J]. Nephrol Dial Transplant, 2020, 35(Suppl 2): ii18-ii22.
[19] FANG X Q, LIU L W, DONG J, et al. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis[J]. J Gastroenterol Hepatol, 2018, 33(4): 774-780.
[20] MAK L Y, WONG D K, CHEUNG K S, et al. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection[J]. Clin Transl Gastroenterol, 2018, 9(6): 163.

Effect of ulinastatin combined with metal biliary stent on pancreatic cancer with extrahepatic biliary obstruction

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	GAO Jie, ZHANG Xiao, WEI Chao. Involvement of differentially expressed miRNA in prognosis of pancreatic cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 173-179.
[2]	WEI Chao, ZHANG Xiao, GAO Jie. Expression of lncRNA and its prognostic value in pancreatic cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 119-126,132.
[3]	WANG Ping, LIU Bingfeng, YANG Yunfeng, CAI Yuwei, TAN Na, YAO Lijuan, LUO Ranran, ZHANG Guo. Mutation frequencies of tumor-related genes in the pancreatic tissues of diet-induced obese mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 182-187.